Prostate cancer
Conditions
Interventions
Collect PET/CT data after intravenous administration of [18F]FSU-880 (approximately 185MBq)that is produced by automated synthetic device. PET/CT data collection is finished in 1 day.
Sponsors
Department of Diagnostic Radiology Kyoto University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Patients having metastatic/recurrent prostate cancer that is confirmed by pathological or imaging diagnosis. 2. Patients who are determined to be appropriate for this study by participating physicians according to the results of physical examination and blood/urine/physiological function tests. 3. Patients who give written informed consent on this study.
Exclusion criteria
Exclusion criteria: 1. Patients having severe communication problem. 2. Patients with severe general condition. 3. Patients having severe renal dysfunction (eGFR<39mL/min/1.73m3) expected to affect the distribution of [18F]FSU-880.. 4. Patients to whom participating physicians judged to be inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vital signs and blood and urine analysis data before and after administration of [18F]FSU-880. Dosimetry calculation data based on serial change of [18F]FSU-880 distribution. Qualitative and semi-quantitative uptake of [18F]FSU-880 in known prostate cancer tissue. | — |
Countries
Japan
Contacts
Public ContactTsuneo Saga
Kyoto University Hospital Department of Diagnostic Radiology
Outcome results
None listed